Abstract Details

Title Headwork as innovative tool for monitoring MABs efficacy in migraine and their influence on work activity

Topic Headache

Presentation(s) P12 - Poster Session 12 (5:30 PM-6:30 PM)

Poster/Presentation
Number 2-010

Objective HEADWORK (HW) is a new evaluation tool, developed specifically to assess the impact on work tasks and reduced productivity of migraineurs. The aim of this study was to test the performance of HW on migraine patients treated with MABs.

Background Monoclonal antibodies (MABs) have been a game changer in the treatment of migraine since their approval. Their efficacy is generally assessed with disease related metrics, but there is an increasing need to evaluate the impact of disease treatment.

Design/Methods

We enrolled 69 patients receiving treatment with MABs at the Headache Centres of IRCCS “C. Besta” (Milan) and IRCCS “C. Mondino” (Pavia). They were assessed with the HEADWORK questionnaire at baseline and at the 3rd (M3) and 6th month (M6) of treatment. HW questionnaire consists of two sections: "Work-related difficulties" (HW1) rates difficulty in general skills, problems solving or starting new task; "Factors contributing to work-related difficulties" (HW2) to asses the negatively impact of some factors, such as noise and brightness of the workplace.

Results Population: 15 M and 54 F, mean age (49.5y±8.6), mean age at onset of disease (18y±7), mean duration of disease (34y±11.6). We observed a marked and consistent and significant reduction in ‘classical’ indicators: monthly migraine days (15±5.7 at baseline, 5±5.8 at M3, 6±6.2 at M6), medications per month (15±8.7 at baseline, 5±12.1 at M3, 6±6.6 at M6), MIDAS (41±43.2 at baseline, 6.5±11.3 at M3, 5±13 at M6), HIT-6 (66±2.8 at baseline, 59±8.7 at M3, 59±8.2 at M6). HW scores paralleled the above parameters: HW1 (20±8.1 at baseline, 11±9 at M3, 7±8.2 at M6), HW2 (9±6 at baseline, 5±4.8 at M3, 3±3.8 at M6).

Conclusions

Our findings confirm the effectiveness of MABs, on clinical markers. HW1 and HW2 also show an extremely positive impact on work related activities. HW appears a suitable tool to assess migraine-related work disability in these patients.

Authors/Disclosures
Cristina Tassorelli PRESENTER	Cristina Tassorelli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Cristina Tassorelli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Cristina Tassorelli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Cristina Tassorelli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Cristina Tassorelli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen. Cristina Tassorelli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Organon. Cristina Tassorelli has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. Cristina Tassorelli has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Cristina Tassorelli has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Organon. Cristina Tassorelli has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva . The institution of Cristina Tassorelli has received research support from Abbvie.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Licia Grazzi, MD (Neurological Institute C Besta)	Dr. Grazzi has received personal compensation in the range of $0-$499 for serving as a Consultant for EliLilly. Dr. Grazzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for allergan-abbvie.

��ɫ��

��ɫ��